Tokyo Tape
Sign in
← Sakai Chemical Industry

Quarterly report · Q2

4078.TEDINET S100PH2A
Period2022-04-01 → 2022-09-30
Filed2022-11-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥42.7bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥80.1bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥39.9bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥3.3bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥4.4bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥3.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥8.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.6bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥4.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥4.5bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥2.9bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥6.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.2bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥3.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥3.3bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥128.4bnat 2022-09-30Cons.Assets
Total assets¥123.9bnat 2022-03-31Cons.Assets
Total assets¥124.5bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥42.6bnat 2022-09-30Cons.Liabilities
Total liabilities¥41.2bnat 2022-03-31Cons.Liabilities
Net assets / equity¥85.8bnat 2022-09-30Cons.Net assets
Net assets / equity¥82.7bnat 2022-03-31Cons.Net assets
Net assets / equity¥82.3bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥11.9bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥10.8bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥11.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥11.8bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥11.2bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥6.6bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥177.482022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.082022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥407.062021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥188.852021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥91.632021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio63.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio63.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2022-04-01 → 2022-09-30¥39.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2022-04-01 → 2022-09-30¥38.6bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥697m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2022-04-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥163m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2022-04-01 → 2022-09-30¥240m
—segment totalrevenue2022-04-01 → 2022-09-30¥43.6bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥42.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥860m
—segment totalsegment profit2022-04-01 → 2022-09-30¥4.4bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥684m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥684m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥977m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2021-04-01 → 2021-09-30¥36.4bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2021-04-01 → 2021-09-30¥35.8bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥548m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2021-04-01 → 2021-09-30¥5.1bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2021-04-01 → 2021-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2021-04-01 → 2021-09-30¥4.1bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥136m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2021-04-01 → 2021-09-30¥233m
—segment totalrevenue2021-04-01 → 2021-09-30¥40.6bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥39.9bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥684m
—segment totalsegment profit2021-04-01 → 2021-09-30¥5.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Provision for directors bonuses sgaPrior1YTDDuration33000000JPY
Provision for directors bonuses sgaCurrentYTDDuration62000000JPY
Retirement benefit expenses sgaPrior1YTDDuration123000000JPY
Retirement benefit expenses sgaCurrentYTDDuration124000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember35809000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember4096000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember39905000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration39905000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember548000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember136000000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember684000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-684000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember36357000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember4233000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember40590000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-684000000JPY
Net salesPrior1YTDDuration39905000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember5101000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember233000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember5334000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-977000000JPY
Operating incomePrior1YTDDuration4356000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember38572000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember4122000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember42694000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration42694000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember697000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember163000000JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember860000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-860000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember39269000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember4285000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember43555000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-860000000JPY
Net salesCurrentYTDDuration42694000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E00780-000ChemicalReportableSegmentsMember4163000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q2r_E00780-000MedicineAndHealthCareReportableSegmentsMember240000000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember4403000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-1136000000JPY
Operating incomeCurrentYTDDuration3267000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-11-09
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第128期第２四半期（自　2022年７月１日　至　2022年９月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)堺化学工業株式会社

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass